SensoDetecthttps://sensodetect.com
Improving The Lives of Patients With Mental IllnessWed, 21 Mar 2018 09:42:11 +0000sv-SE
hourly
1 https://wordpress.org/?v=5.2.3https://sensodetect.com/wp-content/uploads/cache/2017/09/cropped-Favicon_SensoDetect/4276556054.pngSensoDetecthttps://sensodetect.com
3232BERA 3.0 delivered to Boliviahttps://sensodetect.com/bera-3-0-delivered-bolivia/
https://sensodetect.com/bera-3-0-delivered-bolivia/#respondWed, 14 Feb 2018 11:20:18 +0000http://sensodetect.com/?p=841As previously announced, 2018-01-09 and 2018-01-30, SensoDetect has signed an agreement with its Bolivian distributor on the initiation of a study on a specialist hospital in Santa Cruz Central Bolivia. The study, which is part of the marketing campaign, will start in February/March this year and is based on the new BERA 3.0. The first

]]>As previously announced, 2018-01-09 and 2018-01-30, SensoDetect has signed an agreement with its Bolivian distributor on the initiation of a study on a specialist hospital in Santa Cruz Central Bolivia. The study, which is part of the marketing campaign, will start in February/March this year and is based on the new BERA 3.0. The first complete system has now been delivered. This will be tested on a secured group of diagnosed patients and a group of healthy controls.

BERA 3.0 is a portable system that has implemented some new features that ensure the quality of the collected data, the user interface has been improved significantly. For example, the new system supports several different languages and can be customized for multiple user levels. Collected data and all information is encrypted in a secure manner.

The first production Series Arrives shortly. The BERA 3.0 is more cost-effective, easy to produce and portable. It will replace the former version. SensoDetect has as previously announced, 2018-02-12, decided to end the marketing of the previous system and focus entirely on BERA 3.0. As part in our efforts to keep costs down we will terminate the MDD registration of old BERA 2. There is no longer any need for our certification body to carry out its Annual Monitoring of our quality documentation regarding the old BERA 2. However, our management system in accordance with ISO 13485 will be revised in usual order.

“We take an important step further in the launch of the new BERA 3.0. I look forward to the reception of the system in Bolivia and the reactions that it will bring. I also eagerly await the first production series of BERA 3.0 which gives us completely new opportunities in the continued marketing. We will show the market that we have listened, we have acted and now presents an equipment that is upgraded based on the experience and the feed back we received from our users. Now we will take SensoDetect a big leap forward, we leave the old system’s and its restrictions behind us and focus on the BERA 3.0 which gives us an opportunity to offer an appealing solution for the health care system anywhere in the world.”, Says CEO Johan Olson, SensoDetect AB.

]]>https://sensodetect.com/bera-3-0-delivered-bolivia/feed/0SensoDetect discontinues marketing of old BERAhttps://sensodetect.com/sensodetect-discontinues-marketing-old-bera/
https://sensodetect.com/sensodetect-discontinues-marketing-old-bera/#respondMon, 12 Feb 2018 11:18:37 +0000http://sensodetect.com/?p=838SensoDetect has decided to now completely discontinue the marketing of old BERA 2 when the new BERA 3.0 is soon launched. As part of this also closes the MDD registration of old BERA 2 and instead the new BERA will be certified according to the new standard. SensoDetect has decided, as part of the change

]]>SensoDetect has decided to now completely discontinue the marketing of old BERA 2 when the new BERA 3.0 is soon launched. As part of this also closes the MDD registration of old BERA 2 and instead the new BERA will be certified according to the new standard.

SensoDetect has decided, as part of the change and the new product offering, to terminate the old BERA 2 products at the same time keeping the analysis part still separately registered under the name BAS. Thus, from February, we have chosen to end the marketing of BERA 2 permanently. It has in fact already been done since last year but when updates and certification processes are costly and no longer for this product adds anything, we have decided that as said permanently stop marketing the product in this old model and completely focus on the new BERA 3.0 which will be launched according to plan. This has been announced and approved by TUV, our certification partner. This decision is fully in line with the strategy put in place last year, which means that costs are falling, and resources can be redirected. These resources can now instead be fully focused on the new BERA 3.0.

BAS is our analysis tool and remains as a class I product as it remains relevant for analyses both with old and new BERA and for other external systems that may be interesting in coming steps.

“It feels good to be able to take a step further towards the launch of the new BERA 3.0 and I look forward to us now being able to focus all resources on this so that we can reach the approval and certification of this new system as quickly as possible. The old BERA system, we have not marketed for the last year since everyone wants the new one anyway and therefore there is nothing to suggest that we should devote resources to it. Now we take a big step further and at the same time we leave the limitations of the old system and invest in a broader and more appealing solution for the healthcare system.”, says CEO Johan Olson, SensoDetect AB.

]]>https://sensodetect.com/sensodetect-discontinues-marketing-old-bera/feed/0SensoDetect strengthens market focushttps://sensodetect.com/sensodetect-strengthens-market-focus-cooperation-innomedica/
https://sensodetect.com/sensodetect-strengthens-market-focus-cooperation-innomedica/#respondThu, 01 Feb 2018 11:16:30 +0000http://sensodetect.com/?p=836SensoDetect has signed a cooperation agreement with Innomedica from Finland regarding the identification of potential partners and distributors in Europe with a focus on Germany and the UK. Sensodetect have chosen to collaborate with Innomedica from Finland to strengthen the focus on the markets in Europe, mainly Germany and the UK Innomedica Ltd. (founded in

]]>SensoDetect has signed a cooperation agreement with Innomedica from Finland regarding the identification of potential partners and distributors in Europe with a focus on Germany and the UK.

Sensodetect have chosen to collaborate with Innomedica from Finland to strengthen the focus on the markets in Europe, mainly Germany and the UK

Innomedica Ltd. (founded in 1997) is a business development company which has expertise in market analysis and business partnering i.e. distributor network development and technology out-licensing agreements. Innomedica is specialized in cooperating with life science and medical technology companies to support their R&D and upcoming product launches in new territories. Innomedica’s team consists of people with PhD and Master’s degrees in relevant disciplines. All team members have a long, consistent professional background in the field of life sciences.

Since 1997 Innomedica’s has provided services to more than 250 life science, medical technology and bioeconomy companies in Europe, Japan and the USA.

Innomedica has its headquarters in Helsinki, Finland and presence also in Sweden and Japan. Innomedica’s business development services are focused especially on the European and Japanese markets.

Innomedica and SensoDetect start the cooperation immediately and will continue during 2018.

“It is very gratifying that we have initiated a collaboration with such an established actor as Innomedica. It opens a network of partners and distributors and I see the opportunity to get a very clear picture of potential partners and distributors in a relatively short time. With BERA 3.0 in the final stages, it is important that we focus in parallel on the market and Innomedicas Team will be an important complement to our own resources. “says CEO, Johan Olson, SensoDetect AB.

]]>https://sensodetect.com/sensodetect-strengthens-market-focus-cooperation-innomedica/feed/0SensoDetect – Study start in Boliviahttps://sensodetect.com/sensodetect-study-start-bolivia/
https://sensodetect.com/sensodetect-study-start-bolivia/#respondTue, 30 Jan 2018 11:15:09 +0000http://sensodetect.com/?p=834SensoDetect installation and training in Bolivia is planned together with the distributor in one of the hospitals in Santa Cruz. SensoDetect will during the end of February have a person in place to install a first prototype system of BERA 3.0. The Distributor will first be trained in the technology, so they can offer local

]]>SensoDetect installation and training in Bolivia is planned together with the distributor in one of the hospitals in Santa Cruz.

SensoDetect will during the end of February have a person in place to install a first prototype system of BERA 3.0. The Distributor will first be trained in the technology, so they can offer local service and support to the customer and also during training and installation at the hospital. There will be one BERA 3.0 system intended for a study in accordance with the 3-step model SensoDetect, the distributor and the hospital agreed on.

The first step will include tests on known patients (healthy controls and AHDH diagnosed). During step 2, SensoDetect will verify this data so that population variations can be excluded and show that the results are in compliance with physician’s validated diagnoses. Step 3 will give a go ahead to the hospital to continue to use the system for tests which then will be charged per test in accordance with SensoDetects Business model.

“This study is very interesting and important in many ways, it will test a new population while we also will receive input on the new BERA 3.0. As the distributor in Bolivia is both knowledgeable and interested, we see that it is a good start to let them join early in the evaluation of BERA 3.0. It is also the reason why we only start up a single customer. We want to first get feed-back and test the new BERA system before we widen the amounts of clients. It feels very positive and I look forward to the development both in Bolivia and in the rest of South America.”, says CEO, Johan Olson, SensoDetect Ab.

]]>https://sensodetect.com/sensodetect-study-start-bolivia/feed/0New data for OCD (Obsessive-compulsive disorder)https://sensodetect.com/new-data-ocd-obsessive-compulsive-disorder/
https://sensodetect.com/new-data-ocd-obsessive-compulsive-disorder/#respondFri, 26 Jan 2018 11:11:38 +0000http://sensodetect.com/?p=832SensoDetect has now received data from a new group of obsessive-compulsive disorder (OCD) that will be evaluated to supplement BERA 3.0 with additional report if possible. SensoDetect BERA 3.0 will initially focus on ADHD according to previous plan and is supplemented with autism and schizophrenia. These tests will give the doctor a wider material to

]]>SensoDetect has now received data from a new group of obsessive-compulsive disorder (OCD) that will be evaluated to supplement BERA 3.0 with additional report if possible.

SensoDetect BERA 3.0 will initially focus on ADHD according to previous plan and is supplemented with autism and schizophrenia. These tests will give the doctor a wider material to aid in their investigation and diagnosis. The data now collected concerns an additional group with Obsessive-Compulsive Disorder (OCD). These will be analyzed in the spring and if possible added to the BERA 3.0 tests.

As previously communicated, SensoDetect has strengthened the analysis and AI team to be able to intensify both the development of BERA 3.0 and new and exciting data to further create value for customers.

Obsessive Compulsive Disorder (OCD) has a lifetime prevalence of between 1-2.5% and affects women and men equally. People with untreated obsessive-compulsive disorder (OCD) often develop depression why early detection and treatment are central to the healthcare system.

“Could we offer an OCD test as a further part of the response to the psychiatry, it would be unique in its kind. It would increase the value for the psychiatry as OCD is a severe diagnosis that is diverse. A reliable and objective test does not exist as I know of since before and would therefore be a great addition to our BERA tests. However, it is too early to say when we can have such a test ready, but it is very interesting to get in solid data to work with. However, the focus is still on getting the BERA 3.0 on the market for ADHD tests and it goes according to plan.”, says Johan Olson, CEO, SensoDetect AB.

]]>https://sensodetect.com/new-data-ocd-obsessive-compulsive-disorder/feed/0SensoDetect Reinforces with AI skillshttps://sensodetect.com/sensodetect-reinforces-ai-skills/
https://sensodetect.com/sensodetect-reinforces-ai-skills/#respondWed, 24 Jan 2018 11:10:14 +0000http://sensodetect.com/?p=830SensoDetect has strengthened the development and analysis team with additional AI (Artificial Intelligence) and analysis expert. SensoDetect has a strong team working to transform the company from focusing on research and development to market and sales deliverables. Automation, infrastructure and efficiency in everything from routines, handling and analysis. The new BERA 3.0 will offer completely

]]>SensoDetect has strengthened the development and analysis team with additional AI (Artificial Intelligence) and analysis expert.

SensoDetect has a strong team working to transform the company from focusing on research and development to market and sales deliverables. Automation, infrastructure and efficiency in everything from routines, handling and analysis. The new BERA 3.0 will offer completely new and unique possibilities.

SensoDetect will continue to see a large influx of new data and thus the need to also be able to focus resources on automation. By recruiting an AI, maths and statistics expert who also has advanced development skills is a very welcome addition to the organization and we are already seeing new results and streamlining processes.

“It’s always nice when you find resources that are a little out of the ordinary and that can not only help but can add extra drive and efficiency. Knowledge of AI is something I’ve been searching after for a while. As we now complete BERA 3.0, we will increasingly start watching and expanding analysis of the data that are regularly entered. It feels very positive to strengthen this part of our organisation as we want to keep a fast and focused tempo on BERA 3.0 development and deliveries.”, says CEO, Johan Olson, SensoDetect AB.

]]>https://sensodetect.com/sensodetect-reinforces-ai-skills/feed/0SensoDetect Signs Letter Of Agreement for study in Boliviahttps://sensodetect.com/sensodetect-signs-letter-agreement-study-bolivia/
https://sensodetect.com/sensodetect-signs-letter-agreement-study-bolivia/#respondTue, 09 Jan 2018 11:07:26 +0000http://sensodetect.com/?p=827SensoDetect and The Bolivian Distributor have signed a letter of agreement to conduct an initial study in a specialist hospital in central Bolivia. This study will start in February/march this year and will be based on the new BERA 3.0. The agreement is covering three steps that will evaluate and test the BERA 3.0 in

]]>SensoDetect and The Bolivian Distributor have signed a letter of agreement to conduct an initial study in a specialist hospital in central Bolivia. This study will start in February/march this year and will be based on the new BERA 3.0.

The agreement is covering three steps that will evaluate and test the BERA 3.0 in the local population and set up the structure for further commercialisation.

-The first step involves a study being conducted on a secured group of diagnosed patients and a group of healthy controls.

– Then validations of the tests will be done by SensoDetect to ensure that all equipment and handling work on the specific population. This to verify and ensure that the local population corrolates to the data used for the test and that the response provides the intended support to the doctor.

-Step three means that the equipment will be optimized and the distributor trained for service and support. The system of direct diagnosis is set up so that SensoDetect and the Distributor can begin the launch of systems and get paid per use (PPU).

In this case, all steps from study to launch are expected to take 3 to 6 months.

The distributor has previously announced that they have a further six declarations of interest from other hospitals and clinics around Bolivia, which gives a good indication of an interest from Bolivia in general and a potential for relatively rapid expansion from the now specified hospital to a few new hospitals and clinics after the study has been conducted.

“It is very positive that we have now reached an agreement to do a study in a highly reputable hospital in Bolivia. The Distributor’s commitment and experience is very positive and I would like to see an expansion further out of Bolivia to other parts of South America and it is, as I said, mutual. But first we want to establish that all tests are as good for this population as in the past and also that the BERA 3.0 gives the efficiency gain that we believe it will provide both in simplified operation but also in quick responses directly to the referring physician.”says CEO Johan Olson, SensoDetect AB (Publ.)SensoDetect highlights through patented equipment brain stem responses to audio stimuli in order to provide health care clear anomalies and patterns for use primarily within psychiatry. The goal is to increase efficiency in Psychiatry and thus the benefits for health care, society, patients and relatives.

]]>https://sensodetect.com/sensodetect-signs-letter-agreement-study-bolivia/feed/0Version 3.0 – A new compact, portable version of SensoDetect BERA is here!https://sensodetect.com/version-3-0-new-compact-portable-version-sensodetect-bera/
https://sensodetect.com/version-3-0-new-compact-portable-version-sensodetect-bera/#respondTue, 12 Dec 2017 11:05:08 +0000http://sensodetect.com/?p=825SensoDetect Bera V3.0 is undergoing a validation with the aim of being able to CE mark the new product soon. The product is improved on a number of points, including stability, size and ease of use. In the development work, we have, based on the proven basic design of the existing system, modernized and streamlined

]]>SensoDetect Bera V3.0 is undergoing a validation with the aim of being able to CE mark the new product soon. The product is improved on a number of points, including stability, size and ease of use.

In the development work, we have, based on the proven basic design of the existing system, modernized and streamlined the system radically while eliminating bottlenecks in the signal paths. New firmware has been developed for the new version. V3.0 is designed for rational industrial production with all components on a single circuit board. V3.0 is now undergoing an internal validation. The basic structure is essentially the same as in previous versions. Existing documentation will be able to be used in the CE process, which significantly reduces the time for the process.
“I am very pleased that the development work has been conducted at a high pace. SensoDetect can shortly offer users a truly modern, portable and compact version of the unique SensoDetect BERA system in a brand new form; V3.0. A portable system that is also suitable for use in the field. The product has all components on a circuit board, can be machine assembled in its entirety and is therefore very cost effective. The new software makes it possible to use SensoDetect Bera V3.0 with a portable PC or touch pad, which makes the product compact and flexible. The new product has features built-in to ensure that all electrodes are properly applied to the patient and that the measurements are of optimal quality. Our validations so far are very promising, the product is stable and the results show highly reproducible. “Says Johan Olson, CEO, SensoDetect AB.

]]>https://sensodetect.com/version-3-0-new-compact-portable-version-sensodetect-bera/feed/0SensoDetect sign LOI with South Korean distributor after meeting in Swedenhttps://sensodetect.com/sensodetect-sensodetect-sign-loi-south-korean-distributor-meeting-sweden/
https://sensodetect.com/sensodetect-sensodetect-sign-loi-south-korean-distributor-meeting-sweden/#respondWed, 06 Dec 2017 11:02:31 +0000http://sensodetect.com/?p=823SensoDetect has signed a LOI (letter Of Intent) with a South Korean distributor. The parties met for the first time this summer in connection with a major conference in the Copenhagen area and now, after a second meeting, the parties agreed on the bases for further cooperation as clarified in the LOI. The aim is

]]>SensoDetect has signed a LOI (letter Of Intent) with a South Korean distributor. The parties met for the first time this summer in connection with a major conference in the Copenhagen area and now, after a second meeting, the parties agreed on the bases for further cooperation as clarified in the LOI. The aim is to soon take the next step towards a distribution agreement primarily for the South Korean market.

The timetable for cooperation is in line with the plan SensoDetect set up for the launch of the new BERA 3.0. The aim is therefore to set the foundations of the cooperation agreement as soon as possible, beginning at 2018. This agreement is divided into a few steps to ensure a positive development in a large and interesting market.
Initially, SensoDetect, together with the distributor’s healthcare partners in South Korea, make a smaller study to ensure that the tests provide the same response for this population. At the same time, additional opportunities for refinement and development of specific markers for a new population are created. The focus will be on ADHD in the first step.

After the BERA technology has been verified on the local market, the intention is that the distributor should aim to bring the technology as a standard for the diagnosis support of ADHD in South Korea. The first step in the launch is to clinicians with larger volumes and it is expected that current clinics will do at least 600 measurements per year and machine. BERA has a capacity of considerably higher volumes, but SensoDetects strategy is to charge per test, so it requires primarily only a minimum number to sign contracts. ROI (Return On Investment) for BERA is estimated at about 3-6 Months.

The South Korean market even has a slightly higher degree, 27.6% *, of mental illness than other countries ‘ average, about 25% * *. The suicide rate is also high and the country is investing heavily in trying to address the mental ill-health in the country. It has increased the budget for mental ill health from about 18 MUSD 2010 to about 43 MUSD 2014 and has since stated that it wants to invest even harder to get set on mental ill-health. South Korea has a population of just over 51 million and the need for an increase in the budget for mental ill-health is clear. Therefore, the distributor and KOL (Key Opinion Leaders) states that, it is important to find effective solutions. SensoDetect can play an important role in this work and the distributor sees opportunities to standardize the method.

“It is very gratifying to be able to reach this point where we see a clear declaration of intent and where we have already developed a plan for further steps. The interest is very large from the distributor and the KOL they have engaged. We look forward to a smaller study to ensure all the data for this population and at the same time get the opportunity to connect with some of the country’s KOL for further work with market introduction and further research. The South Korean market is particularly interesting for us and with the right partner I see great opportunities”, says CEO Johan Olson, SensoDetect Ab.

]]>https://sensodetect.com/sensodetect-sensodetect-sign-loi-south-korean-distributor-meeting-sweden/feed/0New video presentation by SensoDetecthttps://sensodetect.com/new-video-presentation-sensodetect/
https://sensodetect.com/new-video-presentation-sensodetect/#respondFri, 27 Oct 2017 10:59:15 +0000http://sensodetect.com/?p=819New video presentation published to strengthen work with marketing and sales. The video is part of a larger marketing package that has been developed in accordance with the strategy that the company presented with objectives to reach sales of about 20 million in 2020. The strategy’s focus is to launch BERA 3.0 in the spring

]]>New video presentation published to strengthen work with marketing and sales. The video is part of a larger marketing package that has been developed in accordance with the strategy that the company presented with objectives to reach sales of about 20 million in 2020.

The strategy’s focus is to launch BERA 3.0 in the spring on two focus markets, Germany and the UK. Markets has about 150 million inhabitants and has like the the rest of the world about 20% mental illness among the population.

The markets have a high number of Psychiatrists per inhabitants, seen from a global perspective. With 18 and 19 psychiatrists per 100,000 inhabitants. They are pressed by an ever increasing mental illness, and demand for new and more effective tests seems very clear. Overall, there are about 30,000 psychiatrists who, along with other health care professionals handles about 30 million people with mental illness. The need for an efficient, simple and objective test would seem obvious and that is also why SensoDetect forecasts a very rapid growth in these markets. Our target audience is in addition to the 30,000 psychiatrists also psychologists, general practitioners and some specialist as more and more professionals are involved in investigations in the field of mental illness. SensoDetect, as previously announced, has also broadened its “intended use” so that more professionals can benefit from our technology in their investigations and thus help individuals to faster and more accurate help and diagnosis.

“To reach our goals we focus on finding partners and groups of clinics that can result in a faster deployment. We know that we can minimize the education and startup by targeting these groups since they are working closely together. The strategy and the goals set for 2020 is a challenge but also extremely inspiring and we are very focused!”, says CEO, Johan Olson, SensoDetect Ab.